These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17901887)

  • 1. Onset-potency relationship of nondepolarizing muscle relaxants: a reexamination using simulations.
    Bhatt SB; Amann A; Nigrovic V
    Can J Physiol Pharmacol; 2007 Aug; 85(8):774-82. PubMed ID: 17901887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volume of the effect compartment in simulations of neuromuscular block.
    Nigrovic V; Proost JH; Amann A; Bhatt SB
    Theor Biol Med Model; 2005 Oct; 2():41. PubMed ID: 16202142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the pharmacodynamic parameters in a model for neuromuscular block.
    Nigrovic V; Anton A; Bengez R
    Med Sci Monit; 2004 Dec; 10(12):BR468-76. PubMed ID: 15567978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of the kinetics of neuromuscular block: implications for speed of onset.
    Dilger JP
    Anesth Analg; 2013 Oct; 117(4):792-802. PubMed ID: 23456666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of the neuromuscular block simulated in an anatomical model.
    Nigrovic V; Banoub A; Diefenbach C; Mellinghoff H; Buzello W
    Br J Clin Pharmacol; 1997 Jan; 43(1):55-63. PubMed ID: 9056053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic-dynamic explanation of the rapid onset-offset of rapacuronium.
    Proost JH; Wright PM
    Eur J Anaesthesiol Suppl; 2001; 23():83-9. PubMed ID: 11766253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Speed of action of various muscle relaxants at the neuromuscular junction binding vs. buffering hypothesis.
    Glavinovic MI; Law Min JC; Kapural L; Donati F; Bevan DR
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1181-6. PubMed ID: 8510002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potency and onset time of neuromuscular relaxants.
    Feldman SA
    Anaesthesia; 1997 Apr; 52(4):387-8. PubMed ID: 9135202
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure-pharmacodynamic-pharmacokinetic relationships of steroidal neuromuscular blocking agents.
    Wierda JM; Proost JH
    Eur J Anaesthesiol Suppl; 1995 Sep; 11():45-54. PubMed ID: 8557006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic modeling of muscle relaxants: effect of design issues on results.
    Paul M; Fisher DM
    Anesthesiology; 2002 Mar; 96(3):711-7. PubMed ID: 11873049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle relaxants: pharmacodynamics and pharmacokinetics in different patient groups.
    Booij LH; Vree TB
    Int J Clin Pract; 2000 Oct; 54(8):526-34. PubMed ID: 11198732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to nondepolarizing neuromuscular blocking agents.
    Tschida SJ; Graupe KJ; Hoey LL; Vance-Bryan K
    Pharmacotherapy; 1996; 16(3):409-18. PubMed ID: 8726599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of interaction between two non-depolarizing muscle relaxants: generation of an additive or a supra-additive neuromuscular block.
    Nigrovic V; Amann A
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):157-79. PubMed ID: 15379383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Directions in the development of postsynaptic nondepolarizing muscle relaxants with rapidly developing action].
    Danilov AF; Zhabko EP; Fedorov IuD
    Eksp Klin Farmakol; 1994; 57(4):18-20. PubMed ID: 7950774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competition between acetylcholine and a nondepolarizing muscle relaxant for binding to the postsynaptic receptors at the motor end plate: simulation of twitch strength and neuromuscular block.
    Nigrovic V; Amann A
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):23-51. PubMed ID: 12800806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The future directions in the search for postsynaptic muscle relaxants with rapidly developing and short-term action].
    Danilov AF
    Eksp Klin Farmakol; 1993; 56(4):3-6. PubMed ID: 8220010
    [No Abstract]   [Full Text] [Related]  

  • 17. The relationship between twitch depression and twitch fade during neuromuscular block produced by vecuronium: correlation with the release of acetylcholine.
    Bhatt SB; Kohl J; Amann A; Nigrovic V
    Theor Biol Med Model; 2007 Jul; 4():24. PubMed ID: 17634128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of time of day on the duration of neuromuscular blockade elicited by rocuronium.
    Cheeseman JF; Merry AF; Pawley MD; de Souza RL; Warman GR
    Anaesthesia; 2007 Nov; 62(11):1114-20. PubMed ID: 17924891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The onset time of atracurium is prolonged in patients with sickle cell disease.
    Dulvadestin P; Gilton A; Hernigou P; Marty J
    Anesth Analg; 2008 Jul; 107(1):113-6. PubMed ID: 18635475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy.
    Ihmsen H; Schmidt J; Schwilden H; Schmitt HJ; Muenster T
    Anesthesiology; 2009 May; 110(5):1016-9. PubMed ID: 19352159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.